Filed Pursuant to Rule 424(b)(3)
Registration No. 333-194745
PROSPECTUS SUPPLEMENT
NO. 13 DATED FEBRUARY 23, 2015
TO
PROSPECTUS DATED
JULY 2, 2014
(AS SUPPLEMENTED)
ARCH THERAPEUTICS,
INC.
PROSPECTUS
Up to 45,600,000 Shares of Common Stock
This Prospectus Supplement No. 13 supplements
the prospectus of Arch Therapeutics, Inc. (“the “Company”, “we”, “us”, or “our”)
dated July 2, 2014 (as supplemented to date, the “Prospectus”) with the
following attached document which we filed with the Securities and Exchange Commission on February 23, 2015:
| A. | Our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2015 |
This Prospectus Supplement No. 13 should be read in conjunction
with the Prospectus, which is required to be delivered with this Prospectus Supplement. This
prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency
between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.
This prospectus
supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any
amendments or supplements to it.
Investing in our common stock involves a high degree of risk.
Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are
described in the Prospectus, as amended or supplemented.
You should rely only on the information contained in the
Prospectus, as supplemented or amended by this Prospectus Supplement No. 13 and any other prospectus supplement or amendment thereto.
We have not authorized anyone to provide you with different information.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement No.
13 is February 23, 2015
INDEX TO FILINGS
|
Annex |
The Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2015 |
A |
ANNEX A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 23, 2015
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
|
000-54986 |
|
46-0524102 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
20 William Street, Suite 270 |
|
Wellesley, Massachusetts |
02481 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On February 23, 2015, Arch Therapeutics,
Inc. (the “Company”) issued a press release announcing positive data comparing its AC5™ to a commonly used surgical
hemostasis product. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
herein.
| Item 9.01 | Financial Statements and Exhibit |
(d) Exhibits
Exhibit |
|
Description |
99.1 |
|
Press Release issued by Arch Therapeutics, Inc. on February 23, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC. |
|
|
Dated: February 23, 2015 |
By: |
/s/ Terrence W. Norchi, M.D. |
|
Name: Terrence W. Norchi, M.D. |
|
Title: President, Chief Executive Officer |
EXHIBIT INDEX
Exhibit |
|
Description |
99.1 |
|
Press Release issued by Arch Therapeutics, Inc. on February 23, 2015 |
Exhibit 99.1
Pre-Clinical
Animal Pilot Study Shows Arch Therapeutics’ AC5™ Compared Favorably Versus a Popular Hemostatic Agent
Data
Show Time to Hemostasis with AC5 Significantly Less Than Compared Product
WELLESLEY, MA – February 23, 2015 — Arch
Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™
for use in bleeding during surgical procedures, obtained favorable data from an independent third party pilot animal study that
compared the hemostatic activity of AC5 Surgical Hemostatic Device with a commonly used and commercially available flowable gelatin
(gelatin) hemostatic agent.
In this study, full thickness penetrating wounds were surgically
created in rat livers, which are highly vascularized parenchymal organs, and then either AC5TM or gelatin was applied
in order to stop the bleeding. The time required to stop bleeding, also called time to hemostasis (TTH), was measured.
The average TTH after application of AC5 was significantly less
than 30 seconds, whereas the average TTH after application of gelatin took over four (4) times longer.
The study group intends to submit the data for publication,
at which time additional details would be made publicly available. This marks the first of several planned animal trials comparing
AC5 with currently marketed hemostatic products that are used in surgical procedures.
Terrence W. Norchi, MD, President and CEO of Arch Therapeutics,
said, “This study presents another important performance data point that highlights the potential of AC5. Data to date have
shown that AC5 can stop bleeding rapidly, and this study provided further evidence that AC5 may have superior qualities when compared
to a successful and commonly used hemostatic agent. We highly anticipate the outcomes of further studies, and we remain excited
about the prospects of AC5 and our product platform as we advance the portfolio through a methodical development plan.”
AC5, which contains a self-assembling peptide comprising naturally
occurring amino acids that are not sourced from animals, aims to control bleeding and fluid loss in order to provide faster and
safer surgical and interventional care. AC5 is advancing through development. Gelatin is a commercially available hemostatic product
derived from pig skins. Some surgical products of animal origin present increased risk due to the potential to cause allergic reactions
in some patients. Gelatin products have also been associated with an increased risk of infection, local inflammation, and abnormal
skin wound healing.
The research was led by Rudolf Urbanics, MD, PhD, and Domokos
Csukas, DVM at Semmelweis University Faculty of Medicine in Budapest, Hungary within the Department of Surgical Research and Techniques.
The research was sponsored by Arch. Also part of the research team was Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine
Translational Think Tank in the Department of Ophthalmology at the Medical Faculty Mannheim of the University of Heidelberg in
Germany. Dr. Ellis-Behnke is also affiliated with three U.S. academic institutions, and he is an advisor to and co-founder of Arch.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing
a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing
products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and
safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device ™, is
being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements"
as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange
Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include
any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include,
among other things, references to novel technologies and methods, our business and product development plans and projections, or
market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors.
Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating
as a development stage company, our ability to retain important members of our management team and attract other qualified personnel,
our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any
such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set
forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the
SEC, available at www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Or
Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: rdavis@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024